Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Amebiasis Market Size Changed, over the years?

The market size of amebiasis has seen substantial growth in the past few years. Its projection expresses growth from $0.82 billion in 2024 to $0.88 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. Factors contributing to this growth during the historic period include a rise in amoebic infection cases in tropical regions, inadequate sanitation and hygiene in developing nations, an increase in international travel particularly to endemic zones, heightened awareness about the disease, and scarcity of clean drinking water in rural locations.

How Much Will the Amebiasis Market Be Worth in 2029?

In the coming years, a potent growth is anticipated in the amebiasis market, projected to escalate to $1.14 billion in 2029, with a compound annual growth rate of 6.6%. The growth predicted in this period can be credited to the increasing instances of immune-compromised groups, enhanced government efforts towards sanitation and healthcare infrastructure, rising investment in research for new cures, an amplified emphasis on health strategies to fight parasitic illnesses, and an escalating demand for efficient oral drugs. The period of prediction will witness trends like increasing adoption of combination therapy, vaccine development, progress in drug delivery systems, advancements in pharmaceutical research, and introduction of new antiprotozoal medicines.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21094&type=smp

Which is the Largest Company in the Amebiasis Market?

Major companies operating in the amebiasis market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Siemens Healthineers AG, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Cepheid Inc., Mission Pharmacal Company, Profounda Inc., Zydus Lifesciences Limited

What Are the Main Market Drivers in the Amebiasis Industry?

Rising instances of parasitic infections are projected to stimulate the expansion of the amebiasis market in the future. Diseases caused by parasites, such as protozoa, helminths or ectoparasites, fall into the category of parasitic infections. These parasites survive on or inside a host, feeding off the host’s nutrients. The rise in parasitic infections can be traced back to increased travelling, climate changes, insufficient sanitation, and growing drug resistance, which collectively facilitate these infections’ spread and persistence. Amebiasis, a disease caused by the entamoeba histolytica parasite, is a contributor to parasitic infections, as it invades the intestines and can lead to symptoms like diarrhoea, abdominal pain, tissue damage, and liver abscesses. For example, the Animal and Plant Health Agency, a UK government body, reported in January 2024 that there were 1,071 Parasitic Gastroenteritis (PGE) diagnoses in 2022, with 190 cases of haemonchosis and 95 of nematodirosis. The 2022 haemonchosis case number was quite higher as compared to the previous year. Thus, the growth of the amebiasis market is being fueled by the rising instances of parasitic infections. Impact Of Poor Sanitation On Market Growth

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21094&type=smp

How Is the Amebiasis Market Segments Structured?

The amebiasis market covered in this report is segmented –

1) By Type: Metronidazole, Paromomycin, Tinidazole

2) By Route Of Administration: Oral, Intravenous

3) By Application: Hospital, Pharmacy

Subsegments:

1) By Metronidazole: Oral Metronidazole, Intravenous Metronidazole, Combination Therapy with Metronidazole

2) By Paromomycin: Oral Paromomycin, Paromomycin in Combination with Other Drugs

3) By Tinidazole: Oral Tinidazole, Tinidazole for Severe Infections

What Strategic Trends Are Transforming the Amebiasis Market?

Prominent firms in the amebiasis market are aiming to evolve their products, particularly in relation to oral liquid metronidazole, which is ready-to-use. This enhanced focus is intended to boost both patient satisfaction and procedural success. The pre-prepared aspect of the antibiotic solution, used to tackle illnesses such as amebiasis, is beneficial for patients who find swallowing pills challenging. As an example, Kesin Pharma Corporation, a pharmaceutical company based in the U.S., successfully garnered approval from the U.S. Food and Drug Administration for their product, Likmez (metronidazole) oral suspension, 500 mg/5 mL, in November 2023. This endorsement marked the first occasion where a ready-to-use oral liquid format of metronidazole had been approved. This new format provides a more appealing alternative for children, aiding precise dosage and adherence to treatment plans. The liquid solution adds scope for adjustable dosage, enabling caregivers to fine-tune treatment depending on individual patient requirements and fluctuating levels of infection severity.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/amebiasis-global-market-report

Which Global Regions Offer the Highest Growth in the Amebiasis Market?

North America was the largest region in the amebiasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the amebiasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21094

This Report Delivers Insight On:

1. How big is the amebiasis market, and how is it changing globally?

2. Who are the major companies in the amebiasis market, and how are they performing?

3. What are the key opportunities and risks in the amebiasis market right now?

4. Which products or customer segments are growing the most in the amebiasis market?

5. What factors are helping or slowing down the growth of the amebiasis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model